We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Hope S. Rugo, MD, FASCO
Nadia Harbeck, MD, PhD
Recent updates from adjuvant trials in HR+/HER2- EBC
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Interprofessional Coordination of Adverse Event Management
Maximizing Adherence and Persistence via Patient Engagement
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
John H. Stone, MD, MPH
Emanuel Della Torre, MD, PhD
Yoh Zen, MD, PhD, FRCPath
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Yasmin Genevieve Hernandez-Barco, MD
Avinash Kambadakone-Ramesh, MD, DNB, FRCR
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Emma Culver, BSc, MD, PhD, FRCP
Louisa Catherine Firmin, MBChB, MRCS, FRCR
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
Bart K. Chwalisz, MD
Marcela Marsiglia, MD, PhD
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
Giacomo Quattrocchio, MD
Lynn D. Cornell, MD
Consensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
Warner K. Huh, MD
Kimberly Levinson, MD, MPH
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education